Efficacy and Safety of Combination Olmesartan Medoxomil (Om)+amlodipine Besylate (Aml)+hydrochlorothiazide (Hctz) Based on Severity of Hypertension: The Trinity Study: PP.5.164

Kereiakes, Dean J.; Chrysant, S.G.; Melino, Michael; Fernández, Víctor; Lee, J; Heyrman, Reinilde

doi:10.1097/01.hjh.0000378488.65027.ff

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of prespecified analyses of the TRINITY study were undertaken to assess the efficacy of olmesartan/amlodipine/HCTZ in different patient subgroups. A prespecified subgroup analysis based on baseline hypertension severity (moderate [SeBP <180/110 mmHg] or severe [SeBP ≥180/110 mmHg]) evaluated the mean change from baseline in SeBP and the proportion of patients achieving BP goal with triple combination therapy compared with dual combination therapy [Kereiakes et al 2010]. After 12 weeks of randomized, double-blind treatment, triple combination therapy resulted in significantly greater mean reductions in SeBP from baseline compared with each of the dual Figure 3.…”

Section: Triple Combination Antihypertensive Therapymentioning

confidence: 99%

Olmesartan/amlodipine: blood pressure lowering and beyond in special populations

Erdine

2012

Therapeutic Advances in Cardiovascular Disease

View full text Add to dashboard Cite

Clinical studies and population-based analyses show that in patients with hypertension, the majority cannot control their blood pressure (BP) by treatment with a single antihypertensive agent. Combining agents from different antihypertensive classes with complementary modes of action significantly increases efficacy and is a treatment strategy recommended by European treatment guidelines, particularly in patients at high cardiovascular risk. The combinations of antihypertensive agents recommended by the European guidelines include an angiotensin receptor blocker (ARB) with a calcium channel blocker (CCB). The single-pill combination formulation of the ARB olmesartan medoxomil plus the CCB amlodipine is an effective and well-tolerated treatment that provides greater blood pressure lowering and control than the component monotherapies and favours compliance by not increasing pill burden. Importantly, the efficacy and tolerability of olmesartan plus amlodipine is not affected by age, gender, hypertension severity, diabetes status, race or body mass index. Additional blood pressure lowering effects are observed with stepwise uptitration of olmesartan plus amlodipine with or without hydrochlorothiazide, with more patients achieving blood pressure goals. In addition, olmesartan plus amlodipine has demonstrated effects beyond BP lowering by showing beneficial effects on markers of inflammation, endothelial dysfunction and oxidative stress, as well as metabolic improvements and a reduction in new-onset diabetes incidence in hypertensive patients with metabolic syndrome.

show abstract

Section: Triple Combination Antihypertensive Therapymentioning

confidence: 99%

Olmesartan/amlodipine: blood pressure lowering and beyond in special populations

Erdine

2012

Therapeutic Advances in Cardiovascular Disease

View full text Add to dashboard Cite

show abstract

“…Adverse events were characterized as mostly mild or moderate, and were comparable between the treatment groups [66,67]. Significant BP-lowering benefits of triple therapy were also seen in an ambulatory substudy of 380 patients [68] and in a series of prespecified subgroup analyses based on age, gender, race (Black or non-Black), and hypertension severity (stage 1 or 2), with comparable adverse-event profiles across the regimens in these subsets [69][70][71].…”

Section: Triple-therapy Combinationsmentioning

confidence: 96%

Improving blood pressure control rates by optimizing combination antihypertensive therapy

Epstein

2010

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“… 35 As has been demonstrated in numerous previous studies, the extent of BP reduction obtained with either triple- or dual-therapy in the Trinity trial was greatest in those who received the most antihypertensive medications, and in those who had the highest BP values at baseline. 36 The least squares mean seated BP responses of black (n = 740, B) and nonblack (n = 1718, NB) patients to either two-drug (OM/ AML, AML/HCT or OM/HCT) or to three-drug (OM/AML/ HCT) therapy were not significantly different, although the magnitude of the BP reduction was significantly greater for three-drug therapy (B = 37.1/20.8, NB = 38.9/21.8 mmHg) than for two-drug treatment (B = 28.9 to 30.7/14.5 to 17.0 mmHg, NB = 28.6 to 31.9/14.8 to 18.1 mmHg). 37 TEAEs were comparable in black and nonblack patients across all four treatment groups.…”

Section: Trinity Subgroup Analysesmentioning

confidence: 99%

Three in one: safety, efficacy, and patient acceptability of triple fixed-dose combination medicine in the management of hypertension

Taylor

Ragbir²

2012

PPA

View full text Add to dashboard Cite

Hypertensive patients whose blood pressures are more than 20 mmHg above their goal will often require three or more medications. Careful selection of medications whose actions are complementary or have an improved adverse effect profile when combined can affect not only the blood pressure but also patient acceptance, thus improving persistence in taking the medications as prescribed. This review will highlight the three single-pill three-drug combinations currently available in the US and will address their efficacy, safety, and tolerability. All three include the dihydropyridine calcium-channel blocker, amlodipine, and the thiazide diuretic, hydrochlorothiazide. They each contain a different renin–angiotensin system blocker. One includes the angiotensin-receptor blocker, olmesartan, while another contains valsartan. The third combination includes the direct renin inhibitor, aliskiren. All three fixed-dose combinations (FDC) at maximum doses of each component lowers the blood pressure of patients with stage II hypertension by 37 to 40 mmHg systolic and 21 to 25 mmHg diastolic, which is superior to any two of the components that comprise the three-drug FDC. These drugs are effective in males and females, the elderly, diabetics, minority populations, and patients with metabolic syndrome. Triple-drug FDCs are well tolerated with a low incidence of adverse effects, the most common being peripheral edema related to amlodipine. Extrapolation of data from two-drug FDC suggests that medication compliance (adherence and persistence) should be better with these FDCs than with the individual components taken as separate medications, although additional studies are necessary to confirm this.

show abstract

Efficacy and Safety of Combination Olmesartan Medoxomil (Om)+amlodipine Besylate (Aml)+hydrochlorothiazide (Hctz) Based on Severity of Hypertension: The Trinity Study: PP.5.164

Cited by 3 publications

References 0 publications

Olmesartan/amlodipine: blood pressure lowering and beyond in special populations

Olmesartan/amlodipine: blood pressure lowering and beyond in special populations

Improving blood pressure control rates by optimizing combination antihypertensive therapy

Three in one: safety, efficacy, and patient acceptability of triple fixed-dose combination medicine in the management of hypertension

Contact Info

Product

Resources

About